

SCORE Search Results Details for Application 10591347 and Search Result 20110118_143719_us-10-591-347-2_copy_1567_2124.rng.

Score Home	Retrieve Application	SCORE System	SCORE	Comments /
Page	List	Overview	FAQ	Suggestions

This page gives you Search Results detail for the Application 10591347 and Search Result 20110118_143719_us-10-591-347-2_copy_1567_2124.rng.

[Go Back to previous page](#)

GenCore version 6.3
Copyright (c) 1993 - 2011 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 18, 2011, 23:34:55 ; Search time 1207 Seconds
(without alignments)
9808.281 Million cell updates/sec

Title: US-10-591-347-2_COPY_1567_2124
Perfect score: 558
Sequence: 1 agagacaatgaattaaggga.....atttgaagcacctgaatagg 558

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 18225500 seqs, 10608060480 residues

Total number of hits satisfying chosen parameters: 36451000

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_201023:*
1: geneseqn1:*
2: geneseqn2:*
3: geneseqn3:*
4: geneseqn4:*
5: geneseqn5:*
6: geneseqn6:*
7: geneseqn7:*

8: geneseqn8:*
9: geneseqn9:*

SUMMARIES

Result No.	Score	% Query		DB	ID	Description
		Match	Length			
1	558	100.0	3207	2	ADH68168	Adh68168 DNA encod
2	558	100.0	3207	4	AEF64785	Aef64785 Human pho
3	558	100.0	3207	4	AEK13515	Aek13515 Phosphati
4	558	100.0	3207	4	AEK13519	Aek13519 Phosphati
5	558	100.0	3207	7	ARL60529	Ar160529 Human pho
6	558	100.0	3412	1	AAQ51156	Aaq51156 Human p11
7	558	100.0	3412	4	AED31617	Aed31617 cDNA (SEQ
8	558	100.0	3423	3	ADU05935	Adu05935 Novel bro
9	558	100.0	3424	1	AAS14365	Aas14365 cDNA enco
10	558	100.0	3424	1	ABL59523	Ab159523 Human pho
11	558	100.0	3424	2	ADE85076	Ade85076 Farnesyl
12	558	100.0	3424	4	ADZ00490	Adz00490 p110-beta
13	558	100.0	3424	4	AEH10445	Aeh10445 PIK3CA cD
14	558	100.0	3424	4	AED31618	Aed31618 cDNA (SEQ
15	558	100.0	3424	4	AEG93388	Aeg93388 Human tum
16	558	100.0	3426	6	ARC02473	Arc02473 DNA fragm
17	558	100.0	3724	4	AEK54940	Aek54940 Human PIK
18	558	100.0	3724	5	AER29796	Aer29796 Breast ca
19	558	100.0	3724	7	ARV60468	Arv60468 Human PIK
20	558	100.0	3724	7	ARW65283	Arw65283 Human PIK
21	558	100.0	3724	7	ATM52123	Atm52123 Human PIK
22	558	100.0	3724	7	ATS16021	Ats16021 Human pho
23	558	100.0	3724	8	AWY98731	Awy98731 Human PIK
24	558	100.0	3724	8	AWY98891	Awy98891 Human PIK
25	558	100.0	3724	8	AWY98894	Awy98894 Human PIK
26	558	100.0	3724	9	AXU25358	Axu25358 Human pho
27	558	100.0	3724	9	AYE41305	Aye41305 Human PIK
28	558	100.0	7923	8	AWO77361	Awo77361 Expressio
29	556.4	99.7	3207	4	AEK13514	Aek13514 Phosphati
30	553.2	99.1	4326	8	AWY98838	Awy98838 Human PIK
31	533.8	95.7	3210	4	AEK13511	Aek13511 Phosphati
32	508.4	91.1	3207	1	AAQ51155	Aaq51155 p110 cDNA
33	508.4	91.1	3498	1	AAQ57012	Aaq57012 PtdIns 3-
34	457.8	82.0	3207	8	AWY98836	Awy98836 Human PIK
35	457.8	82.0	3207	8	AWY98892	Awy98892 Human PIK
36	271.6	48.7	459	1	AFS99247	Afs99247 Human tra
37	205	36.7	2397	1	AFS82080	Afs82080 Human tra
38	191.8	34.4	412	2	ABX37274	Abx37274 Bovine ES
39	144.8	25.9	3213	1	AAC65690	Aac65690 Human PI3
40	144.8	25.9	3213	1	AAS14366	Aas14366 cDNA enco
41	144.8	25.9	3213	1	ABV78026	Abv78026 Hypoxia-r
42	144.8	25.9	3213	1	AFS81712	Afs81712 Human tra

43	144.8	25.9	3213	2	ADH17146	Adh17146	Human	pho
44	144.8	25.9	3213	3	ACF87607	Acf87607	Human	SIR
45	144.8	25.9	3213	3	AFI63794	Afi63794	Human	cDN

ALIGNMENTS

RESULT 1

ADH68168

ID ADH68168 standard; DNA; 3207 BP.

XX

AC ADH68168;

XX

DT 25-MAR-2004 (first entry)

XX

DE DNA encoding a PI3K-alpha protein.

XX

KW G protein-coupled receptor; GPCR; phosphoinositide 3-kinase; PI3K; HEAT;

KW Beta-adrenergic receptor kinase 1; Beta-ARK1; cardiant; antiasthmatic;

KW nephrotropic; hypotensive; antianginal; antiarrhythmic;

KW antiarteriosclerotic; antiinflammatory; antidiabetic; antiallergic;

KW antirheumatic; antiarthritic; antiulcer; cardiant; ophthalmological;

KW analgesic; anorectic; antidepressant; tranquilizer; neuroprotective;

KW antiparkinsonian; nootropic; virucide; cytostatic; gene; ds.

XX

OS Homo sapiens.

XX

PN US2003182669-A1.

XX

PD 25-SEP-2003.

XX

PF 19-MAR-2002; 2002US-00101235.

XX

PR 19-MAR-2002; 2002US-00101235.

XX

PA (ROCK/) ROCKMAN H A.

PA (PRAS/) NAGA PRASAD S V.

PA (LAPO/) LAPORTE S A.

PA (BARA/) BARAK L S.

PA (CARO/) CARON M G.

XX

PI Rockman HA, Naga Prasad SV, Laporte SA, Barak LS, Caron MG;

XX

DR WPI; 2004-141485/14.

DR P-PSDB; ADH68169.

XX

PT Screening compounds useful for the treatment of e.g. asthma and angina

PT pectoris involves exposing cell comprising labeled molecule to compounds

PT and comparing locations of labeled molecules in the presence and absence of
PT the compound.
XX
PS Disclosure; SEQ ID NO 7; 71pp; English.
XX
CC The invention relates to a novel method for screening compound(s) for
CC modulating G protein-coupled receptor (GPCR) internalization. The
CC compounds of the invention include modified phosphoinositide 3-kinase
CC (PI3K), modified HEAT domain, and modified Beta-adrenergic receptor
CC kinase 1 (Beta-ARK1). The method involves: exposing a cell comprising
CC labelled molecule to the compound(s); identifying the location of the
CC molecule in the cell; comparing the location in the presence and absence
CC of the compound(s); and correlating difference between the locations. The
CC GPCR modulating compounds have the following activities: cardiatic,
CC antiasthmatic, nephrotropic, hypotensive, antianginal, antiarrhythmic,
CC antiarteriosclerotic, antiinflammatory, antidiabetic, antiallergic,
CC antirheumatic, antiarthritic, antiulcer, cardiatic, ophthalmological,
CC analgesic, anorectic, antidepressant, tranquilizer, neuroprotective,
CC antiparkinsonian, nootropic, virucide, and cytostatic. The compounds are
CC useful for preventing and treating disease associated with GPCR activity
CC and phosphoinositide 3-kinase (PI3K) activity e.g. cardiovascular
CC disease, heart failure, asthma, nephrogenic diabetes insipidus and
CC hypertension, angina pectoris, essential hypertension, myocardial
CC infarction, supraventricular and ventricular arrhythmia, atherosclerosis,
CC renal failure, chronic bronchitis, diabetes, respiratory indications e.g.
CC bronchospasm, emphysema, airway obstruction, upper respiratory
CC indications e.g. rhinitis, seasonal allergies, inflammatory disease,
CC rheumatoid arthritis, chronic inflammatory bowel disease, glaucoma,
CC gastrointestinal indications e.g. acid/peptic disorder, oesophagitis,
CC gastrointestinal hyper-secretion, peptic ulcer, pain, obesity, bulimia
CC nervosa, depression, obsessive compulsive disorder, organ malformation,
CC neurodegenerative disorder e.g. Parkinson's disease, Alzheimer's disease,
CC multiple sclerosis, Epstein-Barr infection and cancer. The modified
CC phosphoinositide 3-kinase compound effectively alters the ability of wild
CC -type PI3K to bind Beta-ARK-1. This polynucleotide sequence represents
CC the DNA encoding a PI3K-alpha protein of the invention
XX
SQ Sequence 3207 BP; 1042 A; 579 C; 674 G; 912 T; 0 U; 0 Other;

Query Match	100.0%;	Score 558;	DB 2;	Length 3207;
Best Local Similarity	100.0%;			
Matches	558;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1555	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1614
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	120

Db	1615	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1674
Qy	121	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1675	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1734
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1735	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1794
Qy	241	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTGTCTGTTCCGGTGC	300
Db	1795	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTGTCTGTTCCGGTGC	1854
Qy	301	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1855	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1914
Qy	361	CTAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	420
Db	1915	CTAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	1974
Qy	421	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTCGAGATGCACAATAAA	480
Db	1975	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTCGAGATGCACAATAAA	2034
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	540
Db	2035	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	2094
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2095	TTGAAGCACCTGAATAGG	2112

RESULT 2

AEF64785

ID AEF64785 standard; cDNA; 3207 BP.

XX

AC AEF64785;

XX

DT 06-APR-2006 (first entry)

XX

DE Human phosphoinositide 3-kinase (PI3K) alpha cDNA.

XX

KW Screening; diagnostic; gene therapy; cardiovascular disease;
 KW cardiovascular-gen.; cardiac failure; cardiant; asthma; antiasthmatic;
 KW nephrogenic diabetes insipidus; nephrotropic; hypertension; hypotensive;
 KW ss; gene; phosphoinositide 3-kinase.

XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1. .3207
FT /*tag= a
FT /product= "Human phosphoinositide 3-kinase (PI3K) gamma
FT protein"
XX
PN US2006026702-A1.
XX
PD 02-FEB-2006.
XX
PF 30-JUL-2004; 2004US-00902137.
XX
PR 19-MAR-2002; 2002US-00101235.
XX
PA (UYDU-) UNIV DUKE.
XX
PI Rockman HA, Naga PSV, Laporte SA, Barak LS, Caron MG;
XX
DR WPI; 2006-153699/16.
DR P-PSDB; AEF64786.
XX
PT Screening compound(s) for modulating GPCR internalization, useful for
PT treating cardiovascular disease, asthma, nephrogenic diabetes insipidus,
PT or hypertension, by providing a cell comprising molecules involved in
PT GPCR internalization.
XX
PS Disclosure; SEQ ID NO 7; 86pp; English.
XX
CC The present invention relates to methods for screening compounds and test
CC solutions for the activity of modulating G protein-coupled receptor
CC (GPCR) internalization. The method involves providing a cell comprising
CC molecules involved in GPCR internalization, where the molecules involved
CC in GPCR internalization comprise beta-adrenergic receptor kinase 1
CC (betaARK1), phosphoinositide 3-kinase (PI3K), GPCR, and arrestin and
CC where at least one of the molecules is detectably labeled. The invention
CC is useful for treating cardiovascular disease, heart failure, asthma,
CC nephrogenic diabetes insipidus and hypertension. The invention is also
CC useful in gene therapy and in diagnostic techniques such as immunoassay.
CC The present sequence is a human phosphoinositide 3-kinase (PI3K) alpha
CC cDNA.
XX
SQ Sequence 3207 BP; 1042 A; 579 C; 674 G; 912 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 4; Length 3207;
Best Local Similarity 100.0%;
Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1555	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1614
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	120
Db	1615	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1674
Qy	121	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTAAATGGAATTCTAGAGAT	180
Db	1675	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTAAATGGAATTCTAGAGAT	1734
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1735	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1794
Qy	241	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1795	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1854
Qy	301	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1855	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1914
Qy	361	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	420
Db	1915	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	1974
Qy	421	ACTAATCAAAGGATTGGGCACTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	480
Db	1975	ACTAATCAAAGGATTGGGCACTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	2034
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	540
Db	2035	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	2094
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2095	TTGAAGCACCTGAATAGG	2112

RESULT 3

AEK13515

ID AEK13515 standard; cDNA; 3207 BP.

XX

AC AEK13515;

XX

DT 02-NOV-2006 (first entry)

XX
DE Phosphatidylinositol 3'-kinase (PI3K) H1047L cDNA SEQ ID NO 54.
XX
KW cytostatic; gene therapy; mutation; diagnosis; prostate tumor; andrology;
KW genitourinary disease; neoplasm; ovary tumor; endocrine disease;
KW genitourinary disease; gynecology and obstetrics; head & neck tumor;
KW bladder tumor; brain tumor; neurological disease; gastrointestinal tumor;
KW gastrointestinal disease; colon tumor; breast tumor; lung tumor;
KW respiratory disease; phosphatidylinositol 3'-kinase; PI3K; mutant; gene;
KW ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1. .3207
FT /*tag= a
FT /product= "Phosphatidylinositol 3'-kinase (PI3K) H1047L"
XX
PN WO2006091899-A2.
XX
PD 31-AUG-2006.
XX
PF 23-FEB-2006; 2006WO-US006751.
XX
PR 24-FEB-2005; 2005US-0656263P.
XX
PA (AMGE-) AMGEN INC.
XX
PI Freeman D, Juan T, Radinsky R;
XX
DR WPI; 2006-648484/67.
DR P-PSDB; AEK13478.
XX
PT New isolated epidermal growth factor receptor (EGFr) polypeptides, useful
PT for treating EGFr-related cancer, e.g. non-small cell lung carcinoma,
PT breast, colon, gastric, brain, bladder, head and neck, ovarian, and
PT prostate carcinomas.
XX
PS Example 1; SEQ ID NO 54; 292pp; English.
XX
CC The invention describes an isolated epidermal growth factor receptor
CC (EPGFr) polypeptide comprising at least one amino acid sequence having
CC 766-1211 amino acids (SEQ ID NO: 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 15, 16,
CC 17, 19, or 20), given in the specification. The isolated polypeptide,
CC polynucleotides, and methods are useful for treating an EGFr-related
CC cancer, e.g. non-small cell lung carcinoma, breast, colon, gastric,
CC brain, bladder, head and neck, ovarian, and prostate carcinomas. This
CC sequence encodes human Phosphatidylinositol 3'-kinase (PI3K) H1047L
CC mutant.

XX

SQ Sequence 3207 BP; 1042 A; 586 C; 670 G; 909 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 4; Length 3207;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1555	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1614
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	120
Db	1615	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1674
Qy	121	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1675	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1734
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1735	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1794
Qy	241	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1795	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1854
Qy	301	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1855	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1914
Qy	361	CTAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	420
Db	1915	CTAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	1974
Qy	421	ACTAATCAAAGGATTGGGCACATTTTCTTTTGGCATTAAAATCTGAGATGCACAATAAA	480
Db	1975	ACTAATCAAAGGATTGGGCACATTTTCTTTTGGCATTAAAATCTGAGATGCACAATAAA	2034
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCCTATTGTCTGCATGTGGGATGTAT	540
Db	2035	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCCTATTGTCTGCATGTGGGATGTAT	2094
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2095	TTGAAGCACCTGAATAGG	2112

RESULT 4

AEK13519

ID AEK13519 standard; cDNA; 3207 BP.

XX

AC AEK13519;

XX

DT 11-JUN-2007 (revised)

DT 02-NOV-2006 (first entry)

XX

DE Phosphatidylinositol 3'-kinase (PI3K) cDNA SEQ ID NO 58.

XX

KW cytostatic; gene therapy; mutation; diagnosis; prostate tumor; andrology;

KW genitourinary disease; neoplasm; ovary tumor; endocrine disease;

KW genitourinary disease; gynecology and obstetrics; head & neck tumor;

KW bladder tumor; brain tumor; neurological disease; gastrointestinal tumor;

KW gastrointestinal disease; colon tumor; breast tumor; lung tumor;

KW respiratory disease; phosphatidylinositol 3'-kinase; PI3K; gene; ss.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT CDS 1..3207

FT /*tag= a

FT /product= "PI3K"

XX

PN W02006091899-A2.

XX

PD 31-AUG-2006.

XX

PF 23-FEB-2006; 2006W0-US006751.

XX

PR 24-FEB-2005; 2005US-0656263P.

XX

PA (AMGE-) AMGEN INC.

XX

PI Freeman D, Juan T, Radinsky R;

XX

DR WPI; 2006-648484/67.

DR P-PSDB; AEK13475.

DR PC:NCBI; gi1763625.

DR PC_ENCPRO:NCBI; gi1763626.

XX

PT New isolated epidermal growth factor receptor (EGFr) polypeptides, useful
PT for treating EGFr-related cancer, e.g. non-small cell lung carcinoma,
PT breast, colon, gastric, brain, bladder, head and neck, ovarian, and
PT prostate carcinomas.

XX

PS Example 1; SEQ ID NO 58; 292pp; English.

XX

CC The invention describes an isolated epidermal growth factor receptor

Query Match 100.0%; Score 558; DB 4; Length 3207;
Best Local Similarity 100.0%;
Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1555	AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1614
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	120
Db	1615	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1674
Qy	121	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTAAATGGAATTTCTAGAGAT	180
Db	1675	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTAAATGGAATTTCTAGAGAT	1734
Qy	181	GAAGTAGCCCGAGATGTATTGCTTGGTAAAAGATTGGCTCCAATCAAACCTGAACAGGCT	240
Db	1735	GAAGTAGCCCGAGATGTATTGCTTGGTAAAAGATTGGCTCCAATCAAACCTGAACAGGCT	1794
Qy	241	ATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTTCGGTGC	300
Db	1795	ATGGAACTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTTCGGTGC	1854
Qy	301	TTGGAAAAATATTTAACAGATGACAAACTTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1855	TTGGAAAAATATTTAACAGATGACAAACTTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1914
Qy	361	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	420
Db	1915	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	1974
Qy	421	ACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTAAAAATCTGAGATGCAACAATAAA	480
Db	1975	ACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTAAAAATCTGAGATGCAACAATAAA	2034

Qy 481 ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTATTGTCGTGCATGTGGGATGTAT 540
 |||
 Db 2035 ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTATTGTCGTGCATGTGGGATGTAT 2094
 Qy 541 TTGAAGCACCTGAATAGG 558
 |||
 Db 2095 TTGAAGCACCTGAATAGG 2112

RESULT 5

ARL60529

ID ARL60529 standard; DNA; 3207 BP.

XX

AC ARL60529;

XX

DT 16-OCT-2008 (first entry)

XX

DE Human phosphoinositide-3-kinase catalytic alpha (PIK3CA) DNA, SEQ ID 23.

XX

KW anti-hiv; antibacterial; antibiotic; bacterial infection; cancer;
 KW chlamydia infection; cns-gen.; coding sequence; cystic fibrosis;
 KW cytostatic; diagnostic test; ds; enzyme inhibition;
 KW escherichia coli infection; haemophilus infection; immune deficiency;
 KW immunostimulant; legionella infection; leishmania infection; leukemia;
 KW lung infection; mycobacterium infection; neutropenia; pharmaceutical;
 KW prophylactic to disease; respiratory-gen.; salmonella infection;
 KW staphylococcus infection; therapeutic; PIK3CA;
 KW phosphoinositide-3-kinase catalytic alpha.

XX

OS Homo sapiens.

XX

PN WO2008026075-A2.

XX

PD 06-MAR-2008.

XX

PF 31-AUG-2007; 2007WO-IB003553.

XX

PR 31-AUG-2006; 2006GB-00017222.

XX

PA (VEHE-) VER HET NEDERLANDS KANKER INST.

PA (ZIEK-) ACAD ZIEKENHUIS LEIDEN.

PA (UYLE-) RIJKSUNIV LEIDEN.

XX

PI Neefjes JJ, Overkleeft HS, Ottenhoff THM, Savage NDL, Tuin AW;

PI Marsman M, Kuijl CP;

XX

DR WPI; 2008-L13796/65.

DR REFSEQ; NM_0062182.

XX

PT Use of protein kinase inhibitor for the manufacture of medicament for
 PT treating intracellular bacterial infection in subject.

XX
 PS Claim 14; SEQ ID NO 23; 238pp; English.
 XX

CC The present invention relates to the use of protein kinase inhibitors for
 CC the manufacture of medicament for treating intracellular bacterial
 CC infections. The inhibitor can be an organic compound or its isomers,
 CC salts, solvates, chemically protected forms, or pro-drugs; an inhibitor
 CC of the protein kinases; a ribozyme or RNAi molecule that targets mRNA
 CC encoding the protein kinase; a polynucleotide encoding a ribozyme or RNAi
 CC molecule; or an antisense polynucleotide that is complementary to a
 CC polynucleotide sequence encoding the protein kinase or its variant or
 CC fragment. The invention was carried out by: (i) screening kinase
 CC inhibitors for an effect on intracellular growth of salmonella, (ii)
 CC synthesis of H-89 variants, (iii) testing the effect of H-89 and H-89
 CC variants on bacterial intracellular growth, (iv) identification of host
 CC cell kinases involved in intracellular salmonella growth using an shRNAi
 CC library, (v) testing kinases for inhibition by H-89 and H-89 variants,
 CC (vi) testing H-89 variants for an inhibitory effect on multi-drug
 CC resistant bacteria and their in vivo antibacterial effect, (vii) siRNA
 CC screening of human kinome, (viii) testing of the PKB/Akt1 inhibitors for
 CC bactericidal effect. The protein kinase inhibitors of the present
 CC invention are used for the manufacture of medicament for treating
 CC intracellular bacterial infection (chlamydia infection, escherichia coli
 CC infection, haemophilus infection, legionella infection, leishmania
 CC infection, mycobacterium infection, salmonella infection, staphylococcus
 CC infection). The method of the invention can be used to target diseases or
 CC conditions in which intracellular bacterial infection is implicated,
 CC namely neutropenia, immunodeficiency, acquired immune deficiency
 CC syndrome, leukemia, cancer patients treated with cytostatic agents, lung
 CC infections associated with cystic fibrosis. The present sequence is the
 CC coding sequence of human phosphoinositide-3-kinase catalytic alpha
 CC polypeptide (PIK3CA), the inhibition of which inhibits intracellular
 CC bacterial growth related to the invention.

XX
 SQ Sequence 3207 BP; 1043 A; 584 C; 669 G; 911 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 7; Length 3207;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1555 AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT 1614
 Qy 61 CCTCTCTCTGAAATCACTGAGCAGGAGAGAAAGATTTCTATGGAGTCACAGACACTATTGT 120
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1615 CCTCTCTCTGAAATCACTGAGCAGGAGAGAAAGATTTCTATGGAGTCACAGACACTATTGT 1674

AAO51156

```

XX
AC  AAQ51156;
XX
DT  25-MAR-2003  (revised)
DT  12-APR-1994  (first entry)
XX
DE  Human p110 cDNA.
XX
KW  Phosphoinositide kinase; PI; p85 subunit; screening; agonist; antagonist;
KW  cell proliferation; inhibition; prophylaxis; therapy; platelets;
KW  neutrophil activity; 3-phosphorylated phosphoinositides; ds.
XX

```

OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..3207
 FT /*tag= a
 FT /note= "PI3- kinase p110"
 XX
 PN W09321328-A1.
 XX
 PD 28-OCT-1993.
 XX
 PF 13-APR-1993; 93WO-GB000761.
 XX
 PR 13-APR-1992; 92GB-00008135.
 XX
 PA (LUDW-) LUDWIG INST CANCER RES.
 XX
 PI Hiles ID, Fry MJ, Dhand R, Waterfield MD, Parker PJ, Otsu M;
 PI Panayotou G, Volinia S, Gout I;
 XX
 DR WPI; 1993-351738/44.
 DR P-PSDB; AAR43342.
 XX
 PT Recombinant polypeptide(s) - with phosphoinositide-3 kinase activity,
 PT useful for controlling cell proliferation.
 XX
 PS Claim 7; Fig 16; 146pp; English.
 XX
 CC Southern blot analysis was performed using a bovine cDNA probe contg. a
 CC fragment of a PI3-kinase-encoding sequence and human cDNA isolated from a
 CC cDNA library constructed from mRNA isolated from the human cell line
 CC KGla. Positive clones were sequenced to give the human PI3 kinase p110
 CC sequence shown. This sequence has 95 percent homology with the bovine
 CC sequence. The domain encoding residues 19- 100 of human p110 is
 CC sufficient to encode the kinase which will associate with the p85 kinase
 CC subunit. The gene may be used to provide a protein with PI3 kinase
 CC activity, and is useful for screening for (ant)agonists of PI3 kinase
 CC activity which could be useful for stimulation or inhibition of cell
 CC proliferation and hence prophylaxis or therapy. Platelet or neutrophil
 CC activity or blood glucose levels can be controlled using the kinase. See
 CC also AAQ51155 and AAQ57522-3. (Updated on 25-MAR-2003 to correct PN
 CC field.) (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 3412 BP; 1128 A; 616 C; 706 G; 962 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 1; Length 3412;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1555	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1614
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTCTATGGAGTCACAGACACTATTGT	120
Db	1615	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTCTATGGAGTCACAGACACTATTGT	1674
Qy	121	GTAACATATCCCCGAAATTTCTACCCAAATGCTTCTGTCTGTTAAATGGAATTTCTAGAGAT	180
Db	1675	GTAACATATCCCCGAAATTTCTACCCAAATGCTTCTGTCTGTTAAATGGAATTTCTAGAGAT	1734
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1735	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1794
Qy	241	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1795	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1854
Qy	301	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1855	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1914
Qy	361	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	420
Db	1915	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	1974
Qy	421	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	480
Db	1975	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	2034
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTTATTGTCGTGCATGTGGGATGTAT	540
Db	2035	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTTATTGTCGTGCATGTGGGATGTAT	2094
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2095	TTGAAGCACCTGAATAGG	2112

RESULT 7

AED31617

ID AED31617 standard; cDNA; 3412 BP.

XX

AC AED31617;

XX

DT 15-DEC-2005 (first entry)

XX

DE cDNA (SEQ ID No:1) encoding human phosphatidylinositol 3-kinase (PIK3CA).
 XX
 KW cancer; neoplasm; phosphatidylinositol 3-kinase; PIK3CA; tumor;
 KW chemotherapy; cytostatic; RNA interference; gene silencing;
 KW antisense therapy; gene; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..3207
 FT /*tag= a
 FT /product= "PIK3CA"
 XX
 PN WO2005091849-A2.
 XX
 PD 06-OCT-2005.
 XX
 PF 18-FEB-2005; 2005WO-US005193.
 XX
 PR 02-MAR-2004; 2004US-0548886P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Samuels Y, Velculescu V, Kinzler KW, Vogelstein B;
 XX
 DR WPI; 2005-713721/73.
 DR P-PSDB; AED31619.
 XX
 PT Assessing cancer in a human suspected of having cancer, by determining a
 PT non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase
 PT (PIK3CA) coding sequence in the body sample from a human.
 XX
 PS Disclosure; SEQ ID NO 1; 107pp; English.
 XX
 CC The invention relates to a method of assessing cancer in a body sample of
 CC a human suspected of having cancer. The method comprises determining a
 CC non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase
 CC (PIK3CA) coding sequence in the body sample, and identifying the human as
 CC likely to have cancer if a non-synonymous, intragenic mutation in PIK3CA
 CC coding sequence is determined in the body sample. Also described are: (1)
 CC a method of inhibiting progression of a tumor in a human; (2) a method of
 CC identifying candidate chemotherapeutic agents; (3) a method for
 CC delivering an appropriate chemotherapeutic drug to a patient in need; and
 CC (4) a set of one or more primers for amplifying and/or sequencing PIK3CA,
 CC the primers selected from forward primers, reverse primers, or sequencing
 CC primers, where the forward primers are selected from sequences given as
 CC SEQ ID NOs 6-165, the reverse primers are selected from sequences given
 CC as SEQ ID NOs 166-325, and the sequencing primers are selected sequences
 CC given as SEQ ID NOs 326-485 in the specification. The method of the

CC invention is useful for assessing cancer in a body sample of a human
 CC suspected of having cancer, inhibiting progression of a tumor in a human,
 CC identifying candidate chemotherapeutic agents, and delivering an
 CC appropriate chemotherapeutic drug to a patient in need. This sequence
 CC encodes human PIK3CA.
 XX

SQ Sequence 3412 BP; 1128 A; 616 C; 706 G; 962 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 4; Length 3412;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1555	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1614
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	120
Db	1615	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1674
Qy	121	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1675	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1734
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1735	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1794
Qy	241	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1795	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1854
Qy	301	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAAATTCAGCTAGTACAGGTC	360
Db	1855	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAAATTCAGCTAGTACAGGTC	1914
Qy	361	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	420
Db	1915	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	1974
Qy	421	ACTAATCAAAGGATTGGGCACATTTTTCTTTTGGCATTAAAACTCGAGATGCACAATAAA	480
Db	1975	ACTAATCAAAGGATTGGGCACATTTTTCTTTTGGCATTAAAACTCGAGATGCACAATAAA	2034
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTATTGTGCGTCATGTGGGATGTAT	540
Db	2035	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTATTGTGCGTCATGTGGGATGTAT	2094
Qy	541	TTGAAGCACCTGAATAGG	558

|||||
 Db 2095 TTGAAGCACCTGAATAGG 2112

RESULT 8

ADU05935

ID ADU05935 standard; DNA; 3423 BP.

XX

AC ADU05935;

XX

DT 27-JAN-2005 (first entry)

XX

DE Novel bronchial cancer-associated human gene SeqID157.

XX

KW bronchial cancer; cytostatic; tumour-associated protein;

KW cancer detection; metastasis; tumour; gene; ds; human.

XX

OS Homo sapiens.

XX

PN DE10316701-A1.

XX

PD 04-NOV-2004.

XX

PF 09-APR-2003; 2003DE-01016701.

XX

PR 09-APR-2003; 2003DE-01016701.

XX

PA (HINZ/) HINZMANN B.

PA (HERM/) HERMANN K.

PA (CAST/) HEIDEN CASTANOS-VELEZ E.

XX

PI Mennerich D, Bruemmendorf T, Heiden E, Hermann K, Kinnemann H;

PI Li X, Roepcke S, Staub E, Hinzmann B, Rosenthal A, Pilarsky C;

XX

DR WPI; 2004-786403/78.

DR P-PSDB; ADU06422.

XX

PT New nucleic acid, and derived proteins, useful for diagnosis of bronchial
 PT cancer and in screening for therapeutic and diagnostic agents.

XX

PS Claim 1; SEQ ID NO 157; 1381pp; German.

XX

CC This invention relates to a novel isolated nucleic acid associated with
 CC bronchial cancer comprising 489 defined sequences given in the
 CC specification. The invention may be useful for the production of
 CC compounds with a cytostatic activity through the inhibition of expression
 CC or activity of tumour-associated proteins. The novel DNA sequences and
 CC the proteins/peptides encoded by them are used for detecting bronchial
 CC cancer or determining the risk of developing it and to screen for

CC specific binding partners of the DNA or protein sequences, where the
 CC binding partners are potentially useful as agents for treating or
 CC diagnosing bronchial cancer. The DNA or protein sequences can also be
 CC used for prognosis, detection of metastases and for secondary treatment
 CC (of tumours that have been stabilised or are no longer detectable).
 CC Detecting abnormal expression of the DNA sequences provides early
 CC diagnosis of bronchial cancers. The present sequence is that of a novel
 CC bronchial cancer-associated human gene sequence of the invention.

XX

SQ Sequence 3423 BP; 1134 A; 618 C; 709 G; 962 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 3; Length 3423;

Best Local Similarity 100.0%;

Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1567	AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1626
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	120
Db	1627	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1686
Qy	121	GTAACATATCCCCGAAATTTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1687	GTAACATATCCCCGAAATTTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1746
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1747	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1806
Qy	241	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1807	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1866
Qy	301	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1867	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1926
Qy	361	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	420
Db	1927	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	1986
Qy	421	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA	480
Db	1987	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA	2046
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTATTGTGTCGTCATGTGGGATGTAT	540

Db 2047 ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTATTGTCGTGCATGTGGGATGTAT 2106

Qy 541 TTGAAGCACCTGAATAGG 558
 |||

Db 2107 TTGAAGCACCTGAATAGG 2124

RESULT 9

AAS14365

ID AAS14365 standard; cDNA; 3424 BP.

XX

AC AAS14365;

XX

DT 11-JUN-2007 (revised)

DT 12-MAR-2002 (first entry)

XX

DE cDNA encoding human p110alpha isoform of PI3-kinase.

XX

KW Human; phosphatidylinositol 3-kinase; PI3K; p110alpha isoform; LASP-1;
 KW cancer; inflammatory disease; ophthalmic disorder; SH3 domain;
 KW autoimmune disease; inflammatory bowel disease; bacterial pneumonia;
 KW Type I diabetes mellitus; cytostatic; immunosuppressive; ss.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT CDS 13..3219

FT /*tag= a

FT /product= "p110alpha isoform of PI3-kinase"

XX

PN WO200185986-A2.

XX

PD 15-NOV-2001.

XX

PF 10-MAY-2001; 2001WO-US015065.

XX

PR 10-MAY-2000; 2000US-0203346P.

XX

PA (ICOS-) ICOS CORP.

XX

PI Sadhu C;

XX

DR WPI; 2002-075252/10.

DR P-PSDB; AAU09687.

DR PC:NCBI; gi472990.

DR PC_ENCPRO:NCBI; gi472991.

XX

PT Identifying a modulator of p110delta polypeptide binding to SH3 domain-
 PT containing polypeptides e.g. LASP-1, comprising allowing the binding

<http://es.ScoreAccessWeb/GetItem.action?AppId=105913...-591-347-2> copy 1567 2124.mg&ItemType=4&startByte=0 (22 of 37)2/3/2011 2:01:13 PM

Db 1807 ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC 1866

Qy 301 TTGAAAAATATTTAACAGATGACAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC 360
|||||

Db 1867 TTGAAAAATATTTAACAGATGACAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC 1926

Qy 361 CTAATAATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG 420
|||||

Db 1927 CTAATAATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG 1986

Qy 421 ACTAATCAAAGGATTGGGCACTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA 480
|||||

Db 1987 ACTAATCAAAGGATTGGGCACTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA 2046

Qy 481 ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT 540
|||||

Db 2047 ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT 2106

Qy 541 TTGAAGCACCTGAATAGG 558
|||||

Db 2107 TTGAAGCACCTGAATAGG 2124

RESULT 10

ABL59523

ID ABL59523 standard; cDNA; 3424 BP.

XX

AC ABL59523;

XX

DT 11-JUN-2007 (revised)

DT 16-JUL-2002 (first entry)

XX

DE Human phosphatidylinositol-3-kinase catalytic alpha cDNA SEQ ID NO:23.

XX

KW Human; phosphatidylinositol-3-kinase catalytic alpha; enzyme; tumour;

KW lipid associated gene; lipid metabolism; lipid synthesis;

KW chromosome 3q26.3; gene; ss.

XX

OS Homo sapiens.

XX

PN WO200227028-A1.

XX

PD 04-APR-2002.

XX

PF 27-SEP-2001; 2001WO-US030366.

XX

PR 28-SEP-2000; 2000US-00676052.

XX

PA (ATAI-) ATAIRGIN TECHNOLOGIES INC.

XX
 PI Skinner MK, Patton JL, Chaudhary J;
 XX

DR WPI; 2002-405056/43.
 DR PC:NCBI; gi472990.
 DR PC_ENCPRO:NCBI; gi472991.
 XX

PT Identifying tumor characteristics in a tissue sample taken from a
 PT patient, involves determining the copy number or expression level of
 PT genes associated with lipid metabolism, synthesis or action.
 XX

PS Example 1; Page 82-83; 113pp; English.
 XX

CC The present invention describes a method for identifying tumour
 CC characteristics, comprising measuring a copy number or expression level
 CC of at least two genes associated with lipid metabolism, synthesis, or
 CC action in cells from a patient tissue sample, and comparing the results
 CC with a copy number or expression level of the genes in a normal cell.
 CC Also described is an array of nucleic acid polymers immobilised on a
 CC solid support, comprising a solid support, at least two different nucleic
 CC acid polymers which are each specific for a different gene associated
 CC with lipid metabolism, synthesis or action, where each nucleic acid
 CC polymer is located at a predetermined position on the solid support, and
 CC the array comprises nucleic acid polymers which are specific for less
 CC than 100 genes other than the selected genes. The method is useful for
 CC determining tumour characteristics in a tissue sample taken from a
 CC patient. The present sequence represents a human lipid-associated gene
 CC related cDNA sequence, which is used in the exemplification of the
 CC present invention
 CC

CC Revised record issued on 11-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX

SQ Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 1; Length 3424;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTCTACACGAGAT 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1567 AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTCTACACGAGAT 1626
 Qy 61 CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT 120
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Db 1627 CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT 1686
 Qy 121 GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT 180
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db	1687	GTAACTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTGTTAAATGGAATTCTAGAGAT	1746
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1747	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1806
Qy	241	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1807	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1866
Qy	301	TTGGAAAAATATTTAACAGATGACAAACTTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1867	TTGGAAAAATATTTAACAGATGACAAACTTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1926
Qy	361	CTAAAAATATGAACAATATTTGGATAAATTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	420
Db	1927	CTAAAAATATGAACAATATTTGGATAAATTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	1986
Qy	421	ACTAATCAAAGGATTGGGCACTTTTCTTTTGGCATTTAAAACTCGAGATGCACAATAAA	480
Db	1987	ACTAATCAAAGGATTGGGCACTTTTCTTTTGGCATTTAAAACTCGAGATGCACAATAAA	2046
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	540
Db	2047	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	2106
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2107	TTGAAGCACCTGAATAGG	2124

PD 08-MAY-2003.
 XX
 PF 30-OCT-2002; 2002WO-US034784.
 XX
 PR 30-OCT-2001; 2001US-0338997P.
 PR 30-OCT-2001; 2001US-0340081P.
 PR 30-OCT-2001; 2001US-0340938P.
 PR 30-OCT-2001; 2001US-0341012P.
 XX
 PA (ORTH) ORTHO CLINICAL DIAGNOSTICS INC.
 XX
 PI Raponi M;
 XX
 DR WPI; 2003-513497/48.
 DR PC:NCBI; gi472990.
 DR PC_ENCPRO:NCBI; gi472991.
 XX
 PT Determining whether a patient will respond to treatment with a farnesyl
 PT transferase inhibitor, by analyzing the expression of gene that is
 PT differentially modulated in the presence of the inhibitor.
 XX
 PS Disclosure; SEQ ID NO 295; 346pp; English.
 XX
 CC The invention relates to a method of determining whether a patient will
 CC respond to treatment with a farnesyl transferase inhibitor (FTI), by
 CC analyzing the expression of gene that is differentially modulated in the
 CC presence of an FTI. The method is useful for determining whether a
 CC patient will respond to treatment with a FTI such as (B)-6-[amino(4-
 CC chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-
 CC methyl-2-(1H)quinolinone, monitoring the therapy of a patient, treating a
 CC patient with leukemia with FTI if the analysis indicates that the patient
 CC will respond. This sequence corresponds to a gene whose expression may be
 CC modulated in the presence of FTI.
 CC
 CC Revised record issued on 11-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 2; Length 3424;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTCTACACGAGAT 60
 |||
 Db 1567 AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTCTACACGAGAT 1626
 |||

Qy 61 CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTCTATGGAGTCACAGACACTATTGT 120
 |||

Db	1627	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1686
Qy	121	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1687	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1746
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1747	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1806
Qy	241	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTGTCTGTTTCGGTGC	300
Db	1807	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTGTCTGTTTCGGTGC	1866
Qy	301	TTGAAAAATATTTAACAGATGACAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1867	TTGAAAAATATTTAACAGATGACAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1926
Qy	361	CTAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	420
Db	1927	CTAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	1986
Qy	421	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	480
Db	1987	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	2046
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	540
Db	2047	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	2106
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2107	TTGAAGCACCTGAATAGG	2124

RESULT 12

ADZ00490

ID ADZ00490 standard; cDNA; 3424 BP.

XX

AC ADZ00490;

XX

DT 11-JUN-2007 (revised)

DT 16-JUN-2005 (first entry)

XX

DE p110-beta coding sequence.

XX

KW ss; Anorectic; Antidiabetic; p110-beta; phosphoinositide 3-kinase; p85;

KW ras; insulin resistance; obesity; gene.

XX

OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 13..3219
 FT /*tag= a
 XX
 PN WO2005031341-A2.
 XX
 PD 07-APR-2005.
 XX
 PF 28-SEP-2004; 2004WO-IB003926.
 XX
 PR 29-SEP-2003; 2003US-0507226P.
 PR 13-JUL-2004; 2004US-0587333P.
 XX
 PA (PFIZ) PFIZER HEALTH AB.
 XX
 PI Bougneres P;
 XX
 DR WPI; 2005-273421/28.
 DR P-PSDB; ADZ00491.
 DR GENBANK; Z29090.
 DR PC:NCBI; gi472990.
 DR PC_ENCPRO:NCBI; gi472991.
 XX
 PT Predicting a subject's likelihood of developing insulin resistance,
 PT useful for treating insulin resistance and obesity, comprises determining
 PT in a subject the identity of an allele at position 100 of a specific
 PT sequence.
 XX
 PS Disclosure; SEQ ID NO 2; 88pp; English.
 XX
 CC This sequence represents the p110-beta gene. p110-beta is a catalytic
 CC subunit of a phosphoinositide 3-kinase, which also comprises a regulatory
 CC subunit of about 85 kD. The p110 protein comprises a kinase domain at the
 CC C-terminus, and a p85 and ras binding domain at the N-terminus. The
 CC method of the invention for predicting a subject's likelihood of
 CC developing insulin resistance comprises determining in a subject the
 CC identity of the nucleotide present at a position corresponding to
 CC position -359 of the p110-beta gene , where the allele comprising the
 CC nucleotide is correlated with an increased or decreased likelihood of
 CC developing insulin resistance. The method of the invention is useful for
 CC treating obesity and insulin resistance and for assessing and conducting
 CC clinical trials of medicaments.
 CC
 CC Revised record issued on 11-JUN-2007 : Enhanced with precomputed
 CC information from BOND.
 XX
 SQ Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 4; Length 3424;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1567	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1626
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	120
Db	1627	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGACACTATTGT	1686
Qy	121	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1687	GTAACATATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1746
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCCTCAATCAAACCTGAACAGGCT	240
Db	1747	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCCTCAATCAAACCTGAACAGGCT	1806
Qy	241	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1807	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1866
Qy	301	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1867	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1926
Qy	361	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	420
Db	1927	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	1986
Qy	421	ACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA	480
Db	1987	ACTAATCAAAGGATTGGGCACTTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA	2046
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTTATGTCGTGCATGTGGGATGTAT	540
Db	2047	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTTATGTCGTGCATGTGGGATGTAT	2106
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2107	TTGAAGCACCTGAATAGG	2124

RESULT 13

AEH10445

ID AEH10445 standard; cDNA; 3424 BP.

XX
AC AEH10445;
XX
DT 11-JUN-2007 (revised)
DT 01-JUN-2006 (first entry)
XX
DE PIK3CA cDNA SEQ ID 831.
XX
KW gene expression; prognosis; diagnosis; DNA microarray;
KW colorectal disease; colon tumor; colorectal tumor; cytostatic;
KW gastrointestinal disease; neoplasm; ss.
XX
OS Unidentified.
XX
PN W02005054508-A2.
XX
PD 16-JUN-2005.
XX
PF 01-DEC-2004; 2004WO-IB004323.
XX
PR 01-DEC-2003; 2003US-0525987P.
PR 01-DEC-2004; 2004US-00000688.
XX
PA (IPSO-) IPSOGEN.
PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
PA (PAOL-) INST PAOLI CALMETTES IPC.
XX
PI Bertucci F, Houlgatte R, Birnbaum D, Debono S;
XX
DR WPI; 2005-435408/44.
DR PC:NCBI; gi472990.
XX
PT Analyzing differential gene expression associated with histopathologic
PT features of colorectal disease, involves detecting overexpression or
PT underexpression of pool of polynucleotide sequences in colon tissues.
XX
PS Claim 1; SEQ ID NO 831; 154pp; English.
XX
CC The invention describes a method of analyzing (M1) differential gene
CC expression associated with histopathologic features of colorectal
CC disease, comprising detecting overexpression or underexpression of a pool
CC of polynucleotide sequences in colon tissues, the pool selected in each
CC of predefined polynucleotide sequence sets chosen from any one of 644
CC sequence sets comprising combinations of SEQ ID No. 1-1596, fully defined
CC in the specification. Also described are: a polynucleotide library (I)
CC useful for the molecular characterization of a colon cancer, comprising
CC or corresponding to a pool of polynucleotide sequences either
CC overexpressed or underexpressed in colon tissue, the pool corresponding
CC to all or part of the polynucleotide sequence chosen from PS1; and

CC assigning (M2) a therapeutic regimen to patient with histopathological
 CC features of colorectal disease, e.g. colon cancer, comprising classifying
 CC the patient having a poor prognosis or a good prognosis on the basis of
 CC (M1), assigning the patient a therapeutic regimen, the therapeutic
 CC regimen comprising no adjuvant chemotherapy if the patient is lymph node
 CC negative and is classified as having a good prognosis or comprising
 CC chemotherapy if the patient has any other combination of lymph node
 CC status and expression profile. (M1) is useful for analyzing differential
 CC gene expression associated with histopathologic features of colorectal
 CC disease. (M1) is useful for analyzing differential gene expression
 CC associated with colon tumors, visceral metastases in colon cancer, lymph
 CC node metastases in colon cancer, MSI phenotype in colon cancer, location
 CC of primary colorectal carcinoma, in colon cancer, and survival and death
 CC of patient in colon cancer, where the analysis comprises detection of
 CC overexpression or underexpression of pool of polynucleotide sequences in
 CC colon tissue, the pool corresponding to specific combination of
 CC polynucleotide sequences from PS1, as given in the specification. (M1) is
 CC useful for detecting, diagnosing, staging, classifying, monitoring or
 CC predicting conditions associated with colorectal cancer. (M1) is useful
 CC for prognosis or diagnosis or colon cancer or for monitoring the
 CC treatment of a patient with colon cancer, which involves implementing
 CC (M1) on nucleic acids from the patient. (M1) is useful for
 CC differentiating a normal cell from a cancer cell, which involves
 CC implementing (M1) on nucleic acids from the cells. (M1) is useful for
 CC selecting appropriate doses and/or schedule of chemotherapeutics and/or
 CC (bio)pharmaceuticals and/or target agents e.g. Irinotecan, 5-fluorouracil
 CC and methotrexate. This sequence represents a polynucleotide identified in
 CC the analysis of differential gene expression associated with
 CC histopathological features of colorectal disease. Note: The sequence data
 CC for this patent is not represented in the printed specification but is
 CC based on sequence information supplied by the European Patent Office.

CC Revised record issued on 11-JUN-2007 : Enhanced with precomputed
 CC information from BOND.

XX

SQ Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 4; Length 3424;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      1 AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT 60
        |||
Db      1567 AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT 1626

Qy      61 CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTCTATGGAGTCACAGACACTATTGT 120
        |||
Db      1627 CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTCTATGGAGTCACAGACACTATTGT 1686
  
```

Qy	121	GTAAGTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1687	GTAAGTATCCCCGAAATTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1746
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1747	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1806
Qy	241	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1807	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1866
Qy	301	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1867	TTGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1926
Qy	361	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	420
Db	1927	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTTACTGAAGAAAGCATTG	1986
Qy	421	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTCGAGATGCACAATAAA	480
Db	1987	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTCGAGATGCACAATAAA	2046
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	540
Db	2047	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT	2106
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2107	TTGAAGCACCTGAATAGG	2124

RESULT 14

AED31618

ID AED31618 standard; cDNA; 3424 BP.

XX

AC AED31618;

XX

DT 15-DEC-2005 (first entry)

XX

DE cDNA (SEQ ID No:2) encoding human phosphatidylinositol 3-kinase (PIK3CA).

XX

KW cancer; neoplasm; phosphatidylinositol 3-kinase; PIK3CA; tumor;

KW chemotherapy; cytostatic; RNA interference; gene silencing;

KW antisense therapy; gene; ss.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers
 FT CDS 13..3219
 FT /*tag= a
 FT /product= "PIK3CA"
 XX

PN WO2005091849-A2.
 XX

PD 06-OCT-2005.
 XX

PF 18-FEB-2005; 2005WO-US005193.
 XX

PR 02-MAR-2004; 2004US-0548886P.
 XX

PA (UYJO) UNIV JOHNS HOPKINS.
 XX

PI Samuels Y, Velculescu V, Kinzler KW, Vogelstein B;
 XX

DR WPI; 2005-713721/73.
 DR P-PSDB; AED31619.
 XX

PT Assessing cancer in a human suspected of having cancer, by determining a
 PT non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase
 PT (PIK3CA) coding sequence in the body sample from a human.
 XX

PS Claim 1; SEQ ID NO 2; 107pp; English.
 XX

CC The invention relates to a method of assessing cancer in a body sample of
 CC a human suspected of having cancer. The method comprises determining a
 CC non-synonymous, intragenic mutation in a phosphatidylinositol 3-kinase
 CC (PIK3CA) coding sequence in the body sample, and identifying the human as
 CC likely to have cancer if a non-synonymous, intragenic mutation in PIK3CA
 CC coding sequence is determined in the body sample. Also described are: (1)
 CC a method of inhibiting progression of a tumor in a human; (2) a method of
 CC identifying candidate chemotherapeutic agents; (3) a method for
 CC delivering an appropriate chemotherapeutic drug to a patient in need; and
 CC (4) a set of one or more primers for amplifying and/or sequencing PIK3CA,
 CC the primers selected from forward primers, reverse primers, or sequencing
 CC primers, where the forward primers are selected from sequences given as
 CC SEQ ID NOs 6-165, the reverse primers are selected from sequences given
 CC as SEQ ID NOs 166-325, and the sequencing primers are selected sequences
 CC given as SEQ ID NOs 326-485 in the specification. The method of the
 CC invention is useful for assessing cancer in a body sample of a human
 CC suspected of having cancer, inhibiting progression of a tumor in a human,
 CC identifying candidate chemotherapeutic agents, and delivering an
 CC appropriate chemotherapeutic drug to a patient in need. This sequence
 CC encodes human PIK3CA.
 XX

SQ Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 4; Length 3424;
 Best Local Similarity 100.0%;
 Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1567	AGAGACAATGAATTAAGGGAAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1626
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTCTATGGAGTCACAGACACTATTGT	120
Db	1627	CCTCTCTCTGAAATCACTGAGCAGGAGAAAGATTTCTATGGAGTCACAGACACTATTGT	1686
Qy	121	GTAACATATCCCCGAAATTTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTTCTAGAGAT	180
Db	1687	GTAACATATCCCCGAAATTTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTTCTAGAGAT	1746
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1747	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1806
Qy	241	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	300
Db	1807	ATGGAACCTTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTTGCTGTTCCGGTGC	1866
Qy	301	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1867	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1926
Qy	361	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	420
Db	1927	CTAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	1986
Qy	421	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA	480
Db	1987	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAACTGAGATGCACAATAAA	2046
Qy	481	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTTATGTCGTGCATGTGGGATGTAT	540
Db	2047	ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCTTATGTCGTGCATGTGGGATGTAT	2106
Qy	541	TTGAAGCACCTGAATAGG	558
Db	2107	TTGAAGCACCTGAATAGG	2124

RESULT 15

AEG93388

ID AEG93388 standard; cDNA; 3424 BP.

XX

AC AEG93388;
XX
DT 11-JUN-2007 (revised)
DT 01-JUN-2006 (first entry)
XX
DE Human tumor cell cDNA SEQ ID NO:884.
XX
KW Gene expression; tumor; ss.
XX
OS Homo sapiens.
XX
PN WO2006036025-A1.
XX
PD 06-APR-2006.
XX
PF 30-SEP-2005; 2005WO-JP018574.
XX
PR 30-SEP-2004; 2004JP-00286259.
PR 28-FEB-2005; 2005JP-00054475.
PR 28-FEB-2005; 2005JP-00054866.
XX
PA (EISA) EISAI CO LTD.
XX
PI Owa T, Yokoi A, Ozawa Y, Kawai T, Ushijima R;
XX
DR WPI; 2006-293404/30.
DR PC:NCBI; gi472990.
DR PC_ENCPRO:NCBI; gi472991.
XX
PT Evaluating sensitivity of a tumor cell to a sulfonamide-containing
PT compound, comprises comparing the expression of specific genes in tumor
PT cells before and after administration of the compound.
XX
PS Claim 1; SEQ ID NO 884; 1405pp; Japanese.
XX
CC The invention relates to a method of evaluating the sensitivity of a
CC tumor cell to a sulfonamide-containing compound, by comparing the
CC expression level of genes in tumor cells obtained from cancer patients
CC before and after administration of the sulfonamide-containing compound
CC and determining the tumor cell to be sensitive to the sulfonamide-
CC containing compound, when the expression amount of genes in the cell is
CC increased compared with the expression amount before administration
CC and/or when the expression amount of one or more genes is decreased
CC compared with the expression amount before administration. The invention
CC also relates to an assay reagent of RNA comprising an oligonucleotide
CC complementary to an RNA which is the transcription product of a gene, and
CC an immunoassay reagent containing the antibody with respect to a protein
CC which is a translation product of the gene. The expression level of the
CC gene, which is the RNA transcription product, is measured using a DNA

CC Revised record issued on 11-JUN-2007 : Enhanced with precomputed
CC information from BOND.

SQ Sequence 3424 BP; 1134 A; 618 C; 709 G; 963 T; 0 U; 0 Other;

Query Match 100.0%; Score 558; DB 4; Length 3424;
Best Local Similarity 100.0%;
Matches 558; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	60
Db	1567	AGAGACAATGAATTAAGGGAAAATGACAAAGAACAGCTCAAAGCAATTTCTACACGAGAT	1626
Qy	61	CCTCTCTCTGAAATCACTGAGCAGGAGAAAAGATTTTCTATGGAGTCACAGACACTATTGT	120
Db	1627	CCTCTCTCTGAAATCACTGAGCAGGAGAAAAGATTTTCTATGGAGTCACAGACACTATTGT	1686
Qy	121	GTAAGTATCCCCGAAATTTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	180
Db	1687	GTAAGTATCCCCGAAATTTCTACCCAAATTGCTTCTGTCTGTTAAATGGAATTCTAGAGAT	1746
Qy	181	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	240
Db	1747	GAAGTAGCCAGATGTATTGCTTGGTAAAAGATTGGCCTCCAATCAAACCTGAACAGGCT	1806
Qy	241	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTGTCTGTTCCGGTGC	300
Db	1807	ATGGAACCTCTGGACTGTAATTACCCAGATCCTATGGTTCGAGGTTTGTCTGTTCCGGTGC	1866
Qy	301	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	360
Db	1867	TTGGAAAAATATTTAACAGATGACAAACTTTCTCAGTATTTAATTCAGCTAGTACAGGTC	1926
Qy	361	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	420
Db	1927	CTAAAAATATGAACAATATTTGGATAACTTGCTTGTGAGATTTTACTGAAGAAAGCATTG	1986
Qy	421	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	480
Db	1987	ACTAATCAAAGGATTGGGCACCTTTTCTTTTGGCATTAAAAATCTGAGATGCACAATAAA	2046

```
Qy      481 ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT 540
          |||
Db      2047 ACAGTTAGCCAGAGGTTTGGCCTGCTTTTGGAGTCCTATTGTCGTGCATGTGGGATGTAT 2106
          |||

Qy      541 TTGAAGCACCTGAATAGG 558
          |||
Db      2107 TTGAAGCACCTGAATAGG 2124
```

Search completed: January 19, 2011, 00:00:35

Job time : 1540 secs

SCORE 0.0